By Ryan Hagglund ( February 23, 2024, 6:20 PM EST) -- The latest chapter in the complex and multifaceted Daiichi Sankyo Inc. v. Seagen Inc.[1] patent dispute — concerning antibody-drug conjugate technology, or ADC, and pitting Seagen against Daiichi and its collaborator, AstraZeneca — concluded recently. On Jan. 16, the Patent Trial and Appeal Board issued a final written decision in a post grant review proceeding, finding all challenged claims of Seagen's U.S. Patent No. 10,808,039 invalid....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.